Physician profile
John R Ellison
NPI 1669427118
$1,294.52
in general payments reported to CMS, 2019-2025
20 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $35.83 · 2021: $153 · 2022: $352 · 2023: $195 · 2024: $235 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.70 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.08 | 2022-2025 | |
| Pfizer INC. | $153.86 | 2020-2023 | |
| Amgen INC. | $125.06 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $114.85 | 2021-2024 | Freestyle Insulinx, Freestyle Libre 3 |
| Novo Nordisk INC | $114.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $85.09 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.53 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $42.68 | 2021-2025 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.10 | 2024 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $23.52 | 2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $19.47 | 2024 | Voquezna |
| Apria Healthcare LLC | $17.32 | 2021 | |
| Exact Sciences Corporation | $15.85 | 2025 | The Cologuard Plus Collection Kit |
| Dexcom, INC. | $15.82 | 2021 | |
| Sanofi Pasteur INC. | $14.69 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $14.44 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.20 | 2023 | Jardiance |
| Allergan, INC. | $11.83 | 2019 | |
| Dynavax Technologies Corporation | $9.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.